Fosarium Fosaprepitant 150 mg Injection is a prescription intravenous antiemetic medicine identified as containing Fosaprepitant 150 mg.

Fosaprepitant is a prodrug of aprepitant and belongs to the neurokinin-1 (NK1) receptor antagonist class.

After intravenous administration, fosaprepitant is converted to aprepitant, which blocks substance P activity at NK1 receptors involved in the vomiting reflex.

It is used with other antiemetic medicines to prevent acute and delayed nausea and vomiting associated with selected chemotherapy regimens.

Fosaprepitant is a supportive-care medicine, not an anticancer chemotherapy drug.

The stated 150 mg strength does not establish the prescribed regimen for every patient. Dosing and combination therapy depend on the approved indication, patient age and chemotherapy protocol.

The exact formulation of Fosarium—whether a powder requiring reconstitution or another approved presentation—must be verified from the product label.

The manufacturer, salt form, vial volume, excipients, storage conditions and approved indications must also be confirmed.

Marketed by Essentials Emporium Enterprises, Fosarium is listed within the oncology supportive-care pharmaceutical category for hospitals, cancer treatment centres and authorized pharmaceutical buyers.

Key Product Features